LCZ696D
Drug
Novartis Pharma AG
Total Payments
$245,431
Transactions
93
Doctors
14
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2018 | $135,111 | 46 | 10 |
| 2017 | $110,320 | 47 | 10 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $98,659 | 18 | 40.2% |
| Consulting Fee | $84,390 | 14 | 34.4% |
| Travel and Lodging | $60,369 | 34 | 24.6% |
| Food and Beverage | $2,013 | 27 | 0.8% |
Payments by Type
General
$146,772
75 transactions
Research
$98,659
18 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| CLCZ696D2301 | Novartis Pharma AG | $90,329 | 4 |
| CLCZ696D2302 | Novartis Pharma AG | $8,330 | 1 |
Top Doctors Receiving Payments for LCZ696D
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , MD | Allergy & Immunology | San Diego, CA | $51,775 | 4 |
| Milton Packer | — | Dallas, TX | $41,616 | 7 |
| , MD | Cardiovascular Disease | Boston, MA | $33,156 | 24 |
| , MD, FRCP, D PHIL, FA | Cardiovascular Disease | Minneapolis, MN | $25,685 | 2 |
| , MD | Internal Medicine | Nashville, TN | $24,605 | 7 |
| , MD | Cardiovascular Disease | Chicago, IL | $17,978 | 4 |
| , MD | Internal Medicine | Mpls, MN | $15,867 | 10 |
| , MD | Advanced Heart Failure and Transplant Cardiology | Charleston, SC | $9,577 | 12 |
| , MB | Nephrology | Minneapolis, MN | $9,090 | 8 |
| , MD | Internal Medicine | Tucson, AZ | $8,496 | 5 |
| , M.D.M.D | Allergy & Immunology | North Charleston, SC | $6,540 | 2 |
| , MD | Neurological Surgery | Grand Rapids, MI | $701.93 | 4 |
| , M.D | Cardiovascular Disease | Rochester, MN | $172.88 | 2 |
| , M.D | Cardiovascular Disease | Boston, MA | $87.88 | 1 |
| , MD | Cardiovascular Disease | Boston, MA | $85.00 | 1 |
Ad
Manufacturing Companies
- Novartis Pharma AG $245,431
Product Information
- Type Drug
- Total Payments $245,431
- Total Doctors 14
- Transactions 93
About LCZ696D
LCZ696D is a drug associated with $245,431 in payments to 14 healthcare providers, recorded across 93 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharma AG.
Payment data is available from 2017 to 2018. In 2018, $135,111 was paid across 46 transactions to 10 doctors.
The most common payment nature for LCZ696D is "Unspecified" ($98,659, 40.2% of total).
LCZ696D is associated with 2 research studies, including "CLCZ696D2301" ($90,329).